Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients

LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organization for Rare Disorders (NORD), a non-profit organization dedicated to helping people with rare diseases. Through this collaboration, Aldeyra and NORD will work to increase awareness of Sjögren-Larsson Syndrome (SLS) and provide patients with opportunities to connect with each other and to access information about their disease, available resources, and ongoing efforts related to diagnosis and treatment.

SLS is an orphan disease characterized by severely dry skin, retinal dysfunction, mental delay, and spasticity. Under the agreement, NORD will develop a multi-phased approach to enhance the ability of the SLS population to communicate and receive optimal care through development of a patient contact registry and other tools, such as social media. This will be conducted through RareLaunch™, NORD's capacity-building and mentor program, through which it works with rare disease patients to develop or evolve disease-specific communities for the purpose of sharing information, accessing resources and learning from medical experts.

Commenting on the agreement, Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, said, "NORD has been a leading voice for people suffering from rare disorders for over 30 years, helping to bring attention to patient populations that are often overlooked and have severe, unmet medical needs. This collaboration provides the opportunity to bridge a gap in awareness of Sjögren-Larsson Syndrome and will further our continued efforts to facilitate a more connected patient community and better educate physicians who could have patients with this condition."

Dr. Brady continued, "With Aldeyra's lead product candidate, NS2, approaching clinical testing, we believe there is an opportunity for significant advancement in how these patients are treated. We look forward to working with our partners at NORD to better understand patient needs and to providing patients with a greater knowledge of all current and future treatment options."

"SLS is a rare disease that has a significant impact on the quality of life of those who are afflicted, as well as their caretakers. We are pleased that Aldeyra is pursuing a viable treatment option for this patient community," commented Peter L. Saltonstall, President and CEO of NORD. "We look forward to working with the Aldeyra team to help create further awareness of this disease and the needs of patients living with it."

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to file Investigational New Drug applications for clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

About the National Organization for Rare Disorders

Established in 1983 by patient organization leaders providing advocacy for the Orphan Drug Act, NORD ( is an independent, nonprofit organization representing the nearly 30 million Americans who have rare diseases, their families, and the patient organizations assisting them. With offices in Quincy, Massachusetts, Washington DC and Danbury, Connecticut, it provides programs of advocacy, education and research, as well as patient assistance programs to help patients obtain needed therapies.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to satisfy the conditions for the second tranche term loan and its ability to maintain compliance with its obligations under the Loan Agreement; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at Additional information will also be set forth in those sections of Aldeyra's quarterly report on Form 10-Q for the quarter ended September 30, 2014, which was filed with the SEC in the fourth quarter of 2014.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 dburke@theruthgroup.comSource:Aldeyra Therapeutics